Skip to main content
SpringerLink
Log in

Sekundärprophylaxe des Schlaganfalls nach PRoFESS und SPARCL

Secondary prevention of stroke according to PRoFESS and SPARCL

  • Schwerpunkt
  • Published:
Der Internist Aims and scope Submit manuscript

Zusammenfassung

Obwohl in den letzten Jahren wesentliche Fortschritte in der Akutbehandlung des Schlaganfalls zu verzeichnen sind (Thrombolyse, Behandlung auf der Stroke-Unit etc.), stellt der Schlaganfall nach wie vor die häufigste zu dauerhafter Behinderung führende Erkrankung dar. Von daher kommt einer effektiven – an die Ätiopathogenese des Schlaganfalls angepassten – Sekundärprävention eine wesentliche Bedeutung zu. In der letzten Zeit sind 2 wichtige Studien erschienen (SPARCL und PRoFESS), die den Stellenwert von Statinen in der Sekundärprävention des Schlaganfalls und die Wirksamkeit unterschiedlicher Thrombozytenfunktionshemmer im direkten Vergleich untersucht haben. In dieser Übersicht werden die Ergebnisse dieser Studien dargestellt und die Implikationen für die Schlaganfallprävention – auch unter Berücksichtigung weiterer aktueller Befunde – diskutiert.

Abstract

Stroke is still the leading cause of long-term major disability in developed countries, although several improvements have been achieved in acute stroke therapy (e.g. thrombolysis, stroke-unit treatment,etc.). Therefore, an effective secondary prevention – guided by the etiology and risk factors of stroke – is of particular importance to reduce stroke morbidity. Recently, two important studies (SPARCL and PRoFESS) analyzed the significance of statin therapy as well as the efficacy of different antiplatelet therapies for secondary stroke prevention. In this review we summarize the results and discuss the implications of these findings – including the most recent data – for stroke prevention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. (n a) (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383–1389

  2. Amarenco P, Benavente O, Goldstein LB et al. (2009) Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke 40: 1405–1409

    Article  CAS  PubMed  Google Scholar 

  3. Amarenco P, Bogousslavsky J, Callahan A et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355: 549–559

    Article  CAS  PubMed  Google Scholar 

  4. Amarenco P, Goldstein LB, Messig M et al. (2009) Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. Stroke 40: 2486–2492

    Article  CAS  PubMed  Google Scholar 

  5. Amarenco P, Goldstein LB, Szarek M et al. (2007) Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 38: 3198–3204

    Article  CAS  PubMed  Google Scholar 

  6. Amarenco P, Labreuche J (2009) Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol 8: 453–463

    Article  CAS  PubMed  Google Scholar 

  7. Amarenco P, Labreuche J, Lavallee P, Touboul PJ (2004) Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35: 2902–2909

    Article  CAS  PubMed  Google Scholar 

  8. Ara R, Pandor A, Stevens J et al. (2009) Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation. Health Technol Assess 13: 1–74, 75–118

    CAS  PubMed  Google Scholar 

  9. Armitage J (2007) The safety of statins in clinical practice. Lancet 370: 1781–1790

    Article  CAS  PubMed  Google Scholar 

  10. Baigent C, Blackwell L, Collins R et al. (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373: 1849–1860

    Article  PubMed  CAS  Google Scholar 

  11. Baigent C, Keech A, Kearney PM et al. (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278

    Article  CAS  PubMed  Google Scholar 

  12. Bhatt DL, Flather MD, Hacke W et al. (2007) Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 49: 1982–1988

    Article  PubMed  Google Scholar 

  13. Bhatt DL, Fox KA, Hacke W et al. (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706–1717

    Article  CAS  PubMed  Google Scholar 

  14. Blanco M, Nombela F, Castellanos M et al. (2007) Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 69: 904–910

    Article  CAS  PubMed  Google Scholar 

  15. Brousseau ME, Schaefer EJ, Wolfe ML et al. (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 350: 1505–1515

    Article  CAS  PubMed  Google Scholar 

  16. CAPRIE Steering Committee (1996) A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329–1339

    Article  Google Scholar 

  17. Carolei A, Chamorro A, Laloux P et al. (2008) Identification and management of polyvascular disease in patients with noncardioembolic ischaemic stroke. Int J Stroke 3: 237–248

    Article  PubMed  Google Scholar 

  18. Chaturvedi S, Zivin J, Breazna A et al. (2009) Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. Neurology 72: 688–694

    Article  CAS  PubMed  Google Scholar 

  19. Collins R, Armitage J, Parish S et al. (2004) Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363: 757–767

    Article  PubMed  CAS  Google Scholar 

  20. Connolly SJ, Pogue J, Hart RG et al. (2009) Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360: 2066–2078

    Article  PubMed  Google Scholar 

  21. Diener HC, Bogousslavsky J, Brass LM et al. (2004) Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364: 331–337

    Article  CAS  PubMed  Google Scholar 

  22. Diener HC, Cunha L, Forbes C et al. (1996) European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143: 1–13

    Article  CAS  PubMed  Google Scholar 

  23. Diener HC, Putzki N (2008) Leitlinien für die Diagnostik und Therapie in der Neurologie, 4. Aufl. Thieme, Stuttgart

  24. Ebrahim S, Sung J, Song YM et al. (2006) Serum cholesterol, haemorrhagic stroke, ischaemic stroke and myocardial infarction: Korean national health system prospective cohort study. BMJ 333: 22

    Article  PubMed  Google Scholar 

  25. Endres M, Laufs U (2006) Discontinuation of statin treatment in stroke patients. Stroke 37: 2640–2643

    Article  CAS  PubMed  Google Scholar 

  26. Goldstein LB, Amarenco P, Lamonte M et al. (2008) Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke 39: 2444–2448

    Article  CAS  PubMed  Google Scholar 

  27. Goldstein LB, Amarenco P, Szarek M et al. (2008) Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology 70: 2364–2370

    Article  CAS  PubMed  Google Scholar 

  28. Grundy SM, Cleeman JI, Merz CN et al. (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44: 720–732

    Article  PubMed  Google Scholar 

  29. Halkes PH, van Gijn J, Kappelle LJ et al. (2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367: 1665–1673

    Article  CAS  PubMed  Google Scholar 

  30. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22

    Article  Google Scholar 

  31. Iso H, Jacobs DR Jr, Wentworth D et al. (1989) Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 320: 904–910

    Article  CAS  PubMed  Google Scholar 

  32. Kennedy J, Hill MD, Ryckborst KJ et al. (2007) Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 6: 961–969

    Article  CAS  PubMed  Google Scholar 

  33. Kongnakorn T, Ward A, Roberts CS et al. (2009) Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. Value Health [Epub ahead of print]

  34. Krasopoulos G, Brister S, Beattie W, Buchanan M (2008) Aspirin „resistance“ and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336: 195–198

    Article  PubMed  CAS  Google Scholar 

  35. Kwa VI, Franke CL, Verbeeten B Jr, Stam J (1998) Silent intracerebral microhemorrhages in patients with ischemic stroke. Amsterdam Vascular Medicine Group. Ann Neurol 44: 372–377

    Article  CAS  PubMed  Google Scholar 

  36. LaRosa JC, Grundy SM, Waters DD et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425–1435

    Article  CAS  PubMed  Google Scholar 

  37. Mattle H, Niederkorn K (2007) Clopidogrel versus acetylsalicylic acid in the secondary prophylaxis of vascular diseases. A commentary on the report of the Institute for Quality and Efficiency in the Health Service. Nervenarzt 78: 206–207

    Article  PubMed  Google Scholar 

  38. Nassief A, Marsh JD (2008) Statin therapy for stroke prevention. Stroke 39: 1042–1048

    Article  CAS  PubMed  Google Scholar 

  39. Pedersen TR, Faergeman O, Kastelein JJ et al. (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294: 2437–2445

    Article  CAS  PubMed  Google Scholar 

  40. Roden DM, Stein CM (2009) Clopidogrel and the concept of high-risk pharmacokinetics. Circulation 119: 2127–2130

    Article  PubMed  Google Scholar 

  41. Sacco RL, Diener HC, Yusuf S et al. (2008) Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 359: 1238–1251

    Article  CAS  PubMed  Google Scholar 

  42. Sacks FM, Pfeffer MA, Moye LA et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and recurrent events trial investigators. N Engl J Med 335: 1001–1009

    Article  CAS  PubMed  Google Scholar 

  43. Sander K, Schulze Horn C, Briesenick C, Sander D (2006) Significant reduction of vascular risk factors within the framework of the population-based intervention project INVADE-a 2-year follow-up study. Dtsch Med Wochenschr 131: 1853–1859

    Article  CAS  PubMed  Google Scholar 

  44. Shepherd J, Blauw GJ, Murphy MB et al. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623–1630

    Article  CAS  PubMed  Google Scholar 

  45. Sillesen H, Amarenco P, Hennerici MG et al. (2008) Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 39: 3297–3302

    Article  CAS  PubMed  Google Scholar 

  46. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339: 1349–1357

    Article  Google Scholar 

  47. Topol EJ, Easton D, Harrington RA et al. (2003) Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation 108: 399–406

    Article  CAS  PubMed  Google Scholar 

  48. Toyoda K, Yasaka M, Iwade K et al. (2008) Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: a prospective, multicenter, observational study. Stroke 39: 1740–1745

    Article  PubMed  Google Scholar 

  49. Undas A, Celinska-Lowenhoff M, Lowenhoff T, Szczeklik A (2006) Statins, fenofibrate and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 4: 1029–1036

    Article  CAS  PubMed  Google Scholar 

  50. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB (2008) Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. Stroke 39: 497–502

    Article  CAS  PubMed  Google Scholar 

  51. Verro P, Gorelick PB, Nguyen D (2008) Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke 39: 1358–1363

    Article  CAS  PubMed  Google Scholar 

  52. Weimar C, Diener HC, Alberts MJ et al. (2009) The Essen stroke risk score predicts recurrent cardiovascular events: a validation within the REduction of Atherothrombosis for Continued Health (REACH) registry. Stroke 40: 350–354

    Article  CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Neurologische Klinik, Medical Park, Thanngasse 15, 83483, Bischofswiesen, Deutschland

    D. Sander

  2. Neurologische Klinik, Klinikum rechts der Isar, Technische Universität München, München, Deutschland

    D. Sander

  3. Neurologische Klinik, Klinikum Traunstein, Traunstein, Deutschland

    T. Etgen

  4. Klinik für Psychiatrie und Psychotherapie, Klinikum rechts der Isar, Technische Universität München, München, Deutschland

    T. Etgen

Authors
  1. D. Sander
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Etgen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. Sander.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sander, D., Etgen, T. Sekundärprophylaxe des Schlaganfalls nach PRoFESS und SPARCL. Internist 50, 1227–1238 (2009). https://doi.org/10.1007/s00108-009-2471-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-009-2471-2

Schlüsselwörter

Keywords

Search

Navigation